CurrentBlue Cross Blue Shield - North CarolinaPolicy N/A

Remote Electrical Neuromodulation for Migraines

Customize your policy alerts

Sign up for all Blue Cross Blue Shield - North Carolina policy alerts

Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs coverage and medical necessity criteria for use of remote electrical neuromodulation (REN) devices (e.g., Nerivio) for acute and preventive treatment of migraine for Blue Cross Blue Shield of North Carolina members.

Policy Summary

PayerBlue Cross Blue Shield - North Carolina

PolicyRemote Electrical Neuromodulation for Migraines

Policy CodePolicy N/A

Change TypeCriteria updated to permit coverage when requirements are metFDA indications expanded

Effective DateJul 16, 2025

Last ReviewJul 16, 2025

Next Review DateApr 1, 2026

Key ActionFor initial preventive use in adults, document insufficient response, contraindication, or intolerance to ≥2 guideline-recommended preventive medications unless an exception applies.

SourceLink

POLICY UPDATE CHANGES

Policy statement updated to medically necessary when the criteria and guidelines have been met.

Expanded indications and FDA clearance history updated to include use in patients 8 years and older and preventive indication.

A4540Applicable service code listed

8 yrsFDA minimum age

18+Covered initial preventive (adults)

8–17Covered initial preventive (pediatrics)

8–12 wkEvaluation period

Coverage and Medical Necessity Criteria

Initial preventive therapy — adults

Covered when ALL of the following are met

Adult initial criteria: Individual is 18 years of age or older AND has a diagnosis of chronic migraines with or without aura AND one of the following additional criteria is met: insufficient response, contraindication, or intolerance to ≥2 guideline-recommended preventive headache medications (e.g., anticonvulsants, antihypertensives, antidepressants, CGRP inhibitors) OR pregnancy, breastfeeding, or planning to conceive OR at risk for or have a history of medication overuse headache OR at risk for drug-drug interactions with medications for comorbid conditions.

Follow step-therapy rule for failure of 2 or more guideline-recommended preventive medications; exceptions allowed as listed.

Initial preventive therapy — pediatric

Covered when ALL of the following are met

Pediatric initial criteria: Individual is 8-17 years of age AND has a diagnosis of chronic migraines with or without aura.

No medication failure requirement is listed for pediatric initial coverage.

Continued use (adults and pediatrics)

Continued use is covered when ALL of the following are met

Continued use criteria: Compliance with ongoing use AND documentation demonstrating clinical benefit evaluated after a minimum of 8–12 weeks, including one or more of: improvements in pain relief or freedom; reduction in headache frequency, duration, or severity; reduction in functional disability; reduction in absenteeism; reduction in concomitant headache medications.8–12 weeks

Clinical benefit may be demonstrated by any of the listed outcome improvements.

Remote electrical neuromodulation (REN) for prevention of migraine when the member does not meet the specific coverage criteria described elsewhere in this policy is considered investigational and not covered.

Use of remote electrical neuromodulation for the treatment of acute migraine attacks is considered investigational and is not covered under this policy.

At initial policy implementation on 5/14/2025, remote electrical neuromodulation (REN) was designated investigational for all applications and therefore not covered. The policy was subsequently updated on 5/6/2026 to clarify that REN may be considered medically necessary when the specified criteria and guideline-based requirements are met.

Billing and Coding

Applicable service codesHCPCS

A4540

Transcutaneous neurostimulation device (e.g., remote electrical neuromodulation) — applicable service code listed by policy

Evaluation period for continued use

Minimum evaluation periodDocumentation demonstrating clinical benefit must be evaluated after a minimum of 8–12 weeks.

Required demonstration of benefitOne or more of: improvements in pain relief or freedom; reduction in headache frequency, duration, or severity; reduction in functional disability; reduction in absenteeism; reduction in concomitant headache medications.

Ongoing requirementCompliance with ongoing use is required at the time of evaluation.

Provider Requirements and Authorization

Prior Authorization

Prior authorization / applicable code

Prior authorization may be required; policy lists A4540 as an applicable service code and notes inclusion does not guarantee reimbursement.

Applicable service code listed: A4540
Inclusion of a code does not guarantee reimbursement

Documentation Required

Initial preventive therapy — adult documentation

For initial preventive use in adults, documentation must show the individual is ≥18 years old with chronic migraine and evidence of insufficient response, contraindication, or intolerance to 2 or more guideline‑recommended preventive headache medications, unless an allowed exception applies (pregnancy/breastfeeding/planning to conceive, risk/history of medication overuse headache, or risk for drug–drug interactions).

Document age (≥18 years) and diagnosis of chronic migraines with or without aura
Document trial and failure or contraindication/intolerance to ≥2 guideline‑recommended preventive medications (e.g., anticonvulsants, antihypertensives, antidepressants, CGRP inhibitors) or a listed exception

Documentation Required

Medical records required for medical necessity reviews

BCBSNC may request medical records to determine medical necessity; letters alone are not sufficient unless they include all specific information needed for the determination.

When records are requested, include complete clinical information rather than relying solely on letters of support or explanation

Denial Risk

Investigational uses — denial risk

Requests for REN for prevention outside the specified coverage criteria or for treatment of acute migraine are considered investigational and may be denied.

Do not submit requests for acute migraine treatment or prevention outside the policy’s listed criteria; such requests are investigational

Clinical Background

Migraine is a neurologic disorder characterized by recurrent moderate to severe headache episodes that can be accompanied by aura, photophobia, nausea, and vomiting. Migraine is classified as episodic (≤14 headache days per month) or chronic (≥15 headache days per month). Remote electrical neuromodulation (REN) is a nonpharmacologic treatment option intended to reduce reliance on systemic medications and the risk of medication overuse.

Key Definitions

Episodic migraine

Definition (episodic migraine)Untreated or unsuccessfully treated headache lasting 4 to 72 hours with at least 2 characteristic features (unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity) and at least one associated symptom (nausea/vomiting or photophobia/phonophobia).

Frequency thresholdGenerally categorized as 14 or fewer headache days per month for episodic migraine.

Clinical features requiredAt least 2 of the characteristic headache features plus at least 1 associated symptom during the headache episode.

Chronic migraine

Definition (chronic migraine)Migraine-like or tension-type headache on 15 or more days per month for more than 3 months, with specified attack features (at least 5 attacks meeting episodic criteria) and ≥8 days/month meeting criteria responsive to migraine-specific therapy.

Frequency threshold15 or more headache days per month for >3 months (distinguishes chronic from episodic).

Diagnostic detailIncludes at least 5 headache attacks meeting episodic migraine criteria (with or without aura) and on more than 8 days per month fulfilling migraine criteria or believed by patient to be migraine and relieved by a triptan or ergot derivative.

Policy Revision History

2026-05-06policy_updateLatest

Policy statement updated to medically necessary when the specified criteria and guidelines are met; description and references updated.

2025-05-14policy_creation

New policy created and implemented as investigational for all applications of remote electrical neuromodulation for migraines; notification given 5/14/2025 for effective date 7/16/2025.

Policy Summary

PayerBlue Cross Blue Shield - North Carolina

PolicyRemote Electrical Neuromodulation for Migraines

Policy CodePolicy N/A

Change TypeCriteria updated to permit coverage when requirements are metFDA indications expanded

Effective DateJul 16, 2025

Last ReviewJul 16, 2025

Next Review DateApr 1, 2026

Key ActionFor initial preventive use in adults, document insufficient response, contraindication, or intolerance to ≥2 guideline-recommended preventive medications unless an exception applies.

SourceLink

On This Page

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

Remote Electrical Neuromodulation for Migraines

Customize your policy alerts

Sign up for all Blue Cross Blue Shield - North Carolina policy alerts

Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Coverage and Medical Necessity Criteria

Initial preventive therapy — adults

Covered when ALL of the following are met

Follow step-therapy rule for failure of 2 or more guideline-recommended preventive medications; exceptions allowed as listed.

Initial preventive therapy — pediatric

Covered when ALL of the following are met

Pediatric initial criteria: Individual is 8-17 years of age AND has a diagnosis of chronic migraines with or without aura.

No medication failure requirement is listed for pediatric initial coverage.

Continued use (adults and pediatrics)

Continued use is covered when ALL of the following are met

Clinical benefit may be demonstrated by any of the listed outcome improvements.

Use of remote electrical neuromodulation for the treatment of acute migraine attacks is considered investigational and is not covered under this policy.

Billing and Coding

Applicable service codesHCPCS

A4540

Transcutaneous neurostimulation device (e.g., remote electrical neuromodulation) — applicable service code listed by policy

Evaluation period for continued use

Minimum evaluation periodDocumentation demonstrating clinical benefit must be evaluated after a minimum of 8–12 weeks.

Ongoing requirementCompliance with ongoing use is required at the time of evaluation.

Provider Requirements and Authorization

Prior Authorization

Prior authorization / applicable code

Prior authorization may be required; policy lists A4540 as an applicable service code and notes inclusion does not guarantee reimbursement.

Applicable service code listed: A4540
Inclusion of a code does not guarantee reimbursement

Documentation Required

Initial preventive therapy — adult documentation

Document age (≥18 years) and diagnosis of chronic migraines with or without aura
Document trial and failure or contraindication/intolerance to ≥2 guideline‑recommended preventive medications (e.g., anticonvulsants, antihypertensives, antidepressants, CGRP inhibitors) or a listed exception

Documentation Required

Medical records required for medical necessity reviews

BCBSNC may request medical records to determine medical necessity; letters alone are not sufficient unless they include all specific information needed for the determination.

When records are requested, include complete clinical information rather than relying solely on letters of support or explanation

Denial Risk

Investigational uses — denial risk

Requests for REN for prevention outside the specified coverage criteria or for treatment of acute migraine are considered investigational and may be denied.

Do not submit requests for acute migraine treatment or prevention outside the policy’s listed criteria; such requests are investigational

Clinical Background

Key Definitions

Episodic migraine

Frequency thresholdGenerally categorized as 14 or fewer headache days per month for episodic migraine.

Clinical features requiredAt least 2 of the characteristic headache features plus at least 1 associated symptom during the headache episode.

Chronic migraine

Frequency threshold15 or more headache days per month for >3 months (distinguishes chronic from episodic).

Policy Revision History

2026-05-06policy_updateLatest

Policy statement updated to medically necessary when the specified criteria and guidelines are met; description and references updated.

2025-05-14policy_creation

New policy created and implemented as investigational for all applications of remote electrical neuromodulation for migraines; notification given 5/14/2025 for effective date 7/16/2025.